Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

February 28, 2011

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Chaturvedi Pravin R

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2022

3. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [JAGX]

(Last)

(First)

(Middle)

C/O JAGUAR HEALTH, INC.,, 200 PINE STREET, SUITE 400

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Chief Scientific Officer

5. If Amendment, Date Original Filed (Month/Day/Year)

(Street)

SAN FRANCISCO, CA 94104

6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy) ⁽¹⁾	⁽²⁾⁽³⁾	07/24/2029	Common Stock	72,364	$ 5.19	D
Stock Option (Right to Buy) ⁽¹⁾	⁽⁴⁾⁽⁵⁾	03/20/2030	Common Stock	15,793	$ 1.338	D
Stock Option (Right to Buy) ⁽¹⁾	⁽⁶⁾⁽⁷⁾	04/05/2031	Common Stock	60,000	$ 5.97	D
Restricted stock units ⁽¹⁾	⁽⁶⁾⁽⁹⁾	04/05/2031	Common Stock	30,000	$ ⁽⁸⁾	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Chaturvedi Pravin R C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400 SAN FRANCISCO, CA 94104			Chief Scientific Officer

Signatures

/s/ Pravin Chaturvedi		03/29/2022
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Granted pursuant to the Issuer's 2014 Stock Incentive Plan.
(2)	The option grant was approved by the issuer's board of directors on July 19, 2019, subject to James J. Bochnowski, the chairman of the board of directors, and Karen S. Wright, the former Chief Financial Officer of the issuer, determining the exact number of option shares to be granted per option based on the issuer's fully diluted shares outstanding followingthe issuer's underwritten public offering consummated on July 23, 2019. Mr. Bochnowski and Ms. Wright certified the exact number of option shares to be granted on 7/24/19, such that the effective date of the option grant was 7/24/19.
(3)	Vests in equal monthly installments beginning on July 24, 2019, with three months of options, or 6,030 options, vested as of the grant date based on the reporting person's numberof years of employment with the issuer, such that the grant is vested in full on the 3-year anniversary of the grant date.
(4)	The option grant was approved by the issuer's board of directors on March 20, 2020.
(5)	The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.
(6)	The option and restricted stock unit grants were approved by the issuer's board of directors on April 5, 2021.
(7)	The option will vest ratably on a monthly basis over 36 months from the grant date, so long as the executive remains employed by the issuer.
(8)	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
(9)	The restricted stock units vest in three equal annual installments beginning on April 5, 2022, the first anniversary of the grant date. Vested shares will be delivered to the reporting person on the vestingdate or dates provided in the grant notice.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.